With 2.05 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.6 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.82 whereas the lowest price it dropped to was $1.54. The 52-week range on ADTX shows that it touched its highest point at $27200.00 and its lowest point at $1.28 during that stretch. It currently has a 1-year price target of $610000.00. Beta for the stock currently stands at 1.36.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ADTX was up-trending over the past week, with a rise of 9.86%, but this was down by -8.24% over a month. Three-month performance dropped to -77.23% while six-month performance fell -96.65%. The stock lost -96.71% in the past year, while it has lost -99.99% so far this year.
Float and Shares Shorts:
At present, 2.43 million ADTX shares are outstanding with a float of 2.43 million shares on hand for trading. On 2025-06-13, short shares totaled 24484.0, which was 114.99999999999999 higher than short shares on 1747267200. In addition to Ms. Corinne D. Pankovcin CPA, M.B.A. as the firm’s Chief Mergers & Acquisitions Officer, Ms. Rowena Albanna serves as its Chief Operating Officer.
Institutional Ownership:
Through their ownership of 0.02715 of ADTX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, ADTX reported revenue of $1018.0 and operating income of -$5608115.0. The EBITDA in the recently reported quarter was -$5538544.0 and diluted EPS was -$8.12.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$112900 being high and -$112900 being low. For ADTX, this leads to a yearly average estimate of -$112900. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
